BeiGene Ltd.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 39
- Registration Number
- NCT03379259
- Locations
- 🇪🇸
Centro Integral Oncologico Clara Campal, Madrid, Spain
🇦🇺Nucleus Network, Melbourne, Victoria, Australia
🇦🇺Linear Clinical Research, Nedlands, Western Australia, Australia
Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With NSCLC
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 805
- Registration Number
- NCT03358875
- Locations
- 🇨🇳
The First Affiliated Hospital of Xian Jiaotong University, Xian, Shaanxi, China
🇱🇹Hospital of Lithuanian University of Health Sciences Kaunas Clinics Branch Oncology Hospital, Kaunas, Lithuania
🇲🇽Health Pharma Professional Research Sa de Cv, Ciudad de Mexico, Mexico
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
- Conditions
- Interventions
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 590
- Registration Number
- NCT03336333
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Augusta University, Augusta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 128
- Registration Number
- NCT03333915
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 217
- Registration Number
- NCT03332017
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Illinois At Chicago, Chicago, Illinois, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 44
- Registration Number
- NCT03332173
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 40
- Registration Number
- NCT03301181
- Locations
- 🇺🇸
West Coast Clinical Trials (WCCT), Cypress, California, United States
A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 70
- Registration Number
- NCT03209973
- Locations
- 🇨🇳
The First Affilliated Hospital of Jilin University, Changchun, Jilin, China
🇨🇳Institute of Hematology and Blood disease hospital,Chinese Academy of Medical Science, Tianjin, Tianjin, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 86
- Registration Number
- NCT03206970
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳The First Hospital of Jilin University, Changchun, Jilin, China
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 91
- Registration Number
- NCT03206918
- Locations
- 🇨🇳
Peking University Peoples Hospital, Beijing, Beijing, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China